Eli Lilly

GLP-1 obesity drug rollout and market expansion

105 clusters · 510 sources · last updated about 12 hours ago

Latest: Novo Nordisk reports pediatric obesity trial success amid market pressure

Novo Nordisk continues to expand its GLP-1 market presence, maintaining approximately a 43% global market share for obesity and diabetes treatments despite competition from Eli Lilly. The oral Wegovy pill remains a prima

Brazil ANVISA expands product safety enforcement

31 clusters · 228 sources · last updated 1 day ago

Latest: Brazil combats illegal weight-loss drug market as Anvisa fast-tracks generics

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

GLP-1 drugs: clinical trends, safety, and market shifts

246 clusters · 894 sources · last updated 2 days ago

Latest: Medical experts propose management system for GLP-1 obesity drugs

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

South Korean medical tech and AI sovereignty expansion

4 clusters · 6 sources · last updated 2 days ago

Latest: South Korean tech firms develop specialized AI to ensure data sovereignty

South Korean medical technology and biotechnology companies are expanding their global footprint through specialized innovations and high-value technology exports. In the medical AI and device sectors, firms are securin

Solana sees surging ETF inflows and institutional interest

24 clusters · 94 sources · last updated 2 days ago

Latest: Solana leads blockchain app revenue and RWA transaction volume

Solana (SOL) continues to experience significant market activity driven by institutional demand and network evolution. US-based spot Solana ETFs have maintained sustained inflows, including a record single-day inflow of

Novo Nordisk AI integration and market developments

5 clusters · 14 sources · last updated 3 days ago

Latest: Novo Nordisk executes 9 billion DKK share buyback amid pipeline shifts

Novo Nordisk continues to integrate artificial intelligence into its pharmaceutical development through strategic partnerships. Following its collaboration with H1, the company established an AI innovation center and co-

Healthcare and biotechnology ETF investment options

2 clusters · 3 sources · last updated 3 days ago

Latest: Healthcare ETFs: Comparing broad sector funds and pharmaceutical specialists

Investors in the healthcare sector are evaluating various exchange-traded funds (ETFs) to achieve specific exposure to biotechnology, pharmaceuticals, and broader medical services. Initial assessments highlight a range

Weight-loss medication and cosmetic procedure trends

2 clusters · 5 sources · last updated 4 days ago

Latest: Medical experts discuss weight loss aesthetics and gynecomastia

The widespread use of GLP-1 weight-loss medications, including Wegovy and Zepbound, is driving an increase in demand for cosmetic procedures, particularly among men. As patients experience significant weight loss, they a

Eli Lilly retatrutide development and black market issues

8 clusters · 26 sources · last updated 4 days ago

Latest: Retatrutid shows significant weight loss in Phase 3 trials

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in

Novartis CAR T cell therapy trial suspensions

2 clusters · 34 sources · last updated 5 days ago

Latest: Novartis shares plunge following dual clinical trial failures

Novartis has halted eight clinical trials involving an experimental CAR T cell therapy following three deaths. The fatalities were linked to immune effector cell-associated hemophagocytic syndrome (IEC-HS), a condition w

Health alerts over unregulated pharmaceutical products

4 clusters · 23 sources · last updated 5 days ago

Latest: ANMAT issues alert over illegal weight loss injections

Health authorities in the Americas continue to issue warnings regarding the sale of unregulated supplements and unauthorized pharmaceutical products containing undeclared active ingredients. In the United States and Mex

Eurozone economic performance and inflation trends 2026

11 clusters · 63 sources · last updated 5 days ago

Latest: Eurozone economy shows recovery in Q2 2026

In Q2 2026, the Eurozone economy grew by 0.6% compared to the first quarter, following a period of stagnation. Growth rates varied significantly by member state. Ireland recorded an explosive 10.2% quarterly GDP increase

Advancements in Alzheimer's blood tests and drug safety

12 clusters · 62 sources · last updated 6 days ago

Latest: Alzheimer's research identifies age-50 brain changes and new prevention trials

Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of blood-based testing. While plasma p-tau217 remains a key indicator, studies suggest its predictive power in symptom-f

GLP-1 drug medical and economic impact

2 clusters · 5 sources · last updated 7 days ago

Latest: Ozempic: mechanism, uses, and weight loss effects

GLP-1 receptor agonist drugs, including semaglutide (the active ingredient in Ozempic), are significantly impacting the treatment of obesity, diabetes, and various cardiovascular and kidney diseases. These medications ha

Eli Lilly acquisition of Merida Biosciences

2 clusters · 19 sources · last updated 8 days ago

Latest: Eli Lilly to acquire Merida Biosciences for up to $2.875 billion

Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, a biotechnology firm based in Cambridge, Massachusetts, for a total value of approximately $2.88 billion. The deal structure co

Eli Lilly revenue growth and market activity

2 clusters · 3 sources · last updated 8 days ago

Latest: Eli Lilly sees revenue growth driven by GLP-1 therapies

Eli Lilly and Company has experienced significant revenue growth, reporting $23 billion for the second quarter, a 48% year-over-year increase. This growth is primarily attributed to high demand for its GLP-1 metabolic th

Corporate GLP-1 medication coverage trends

3 clusters · 9 sources · last updated 12 days ago

Latest: Bank of America maintains GLP-1 coverage for obesity

Major U.S. employers are adopting diverging strategies regarding the coverage of GLP-1 weight-loss medications, such as Ozempic, Wegovy, and Zepbound, due to rising costs. Bank of America has committed over $250 million

FDA approval of Mounjaro for cardiovascular risk

2 clusters · 16 sources · last updated 12 days ago

Latest: FDA approves Eli Lilly's Mounjaro to reduce heart attack and stroke risk

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly’s diabetes medication, Mounjaro (tirzepatide), to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at

Advances in obesity and weight management treatments

3 clusters · 8 sources · last updated 15 days ago

Latest: Obesity treatment shifts toward oral medications and dietary integration

Medical approaches to obesity and weight management are expanding through a combination of pharmaceutical, surgical, and technological innovations. While bariatric surgeries like sleeve gastrectomies and gastric bypasses

Growth and regulation in pharmaceutical cold chain logistics

3 clusters · 7 sources · last updated 16 days ago

Latest: Pharmaceutical logistics transform to handle temperature-sensitive drugs

The pharmaceutical logistics sector is expanding due to a rising demand for temperature-sensitive medical treatments, particularly biologics and GLP-1 medications used for diabetes and obesity. In the United States, Fed

Advancements in Alzheimer's blood test detection

2 clusters · 4 sources · last updated 17 days ago

Latest: FDA clears two new blood tests for Alzheimer's detection

Research led by neurologist Allal Boutjankout and NYU professor Thomas Wisniewski demonstrated that blood tests measuring plasma levels of beta-amyloid, tau, and inflammation-related proteins can identify Alzheimer’s dis

South Korea GLP-1 obesity drug surge and illegal imports

3 clusters · 8 sources · last updated 19 days ago

Latest: South Korea sees 3.5x surge in illegal Wegovy and Mounjaro imports

Within ten months of their market launch in August 2023, GLP-1 obesity medicines—including Mounjaro and Wegovy—were prescribed more than 1.5 million times in South Korea. Monthly dispensing rose from under 2,000 prescrip

Brazil pharmaceutical and pharmacy retail market growth

2 clusters · 11 sources · last updated 21 days ago

Latest: Private label brands reach R$ 2.98 billion in Brazil's pharmacy channel

The Brazilian pharmaceutical and pharmacy retail market has shown significant growth through mid-2026. Total market revenue reached R$ 279.7 billion for the 12 months ending July 2026, a 13.71% increase driven largely by

Brazil cannabis-derived CBD regulation

2 clusters · 8 sources · last updated 22 days ago

Latest: Anvisa and Dinavisa sign agreement to combat illegal products

Brazil’s National Health Surveillance Agency (Anvisa) is finalizing new regulations to govern the magistral manipulation of cannabidiol (CBD) preparations. The agency has classified this regulatory work as a priority to

Healthcare sector investment trends

2 clusters · 5 sources · last updated 24 days ago

Latest: Healthcare sector offers diversification against tech concentration

Financial analysts are identifying the healthcare sector as a strategic hedge and diversification tool against the high concentration and volatility of technology and artificial intelligence (AI) stocks. Initial observa

Global pharmaceutical and biotech industry trends

2 clusters · 3 sources · last updated 27 days ago

Latest: Pharmaceutical industry sees leadership shifts and FDA approvals

The global biotechnology and pharmaceutical sectors have experienced significant activity driven by strategic acquisitions and regulatory milestones. Between January and May 2026, the biotech sector saw 201 mergers and a

Pharmaceutical manufacturing investment trends

4 clusters · 22 sources · last updated 27 days ago

Latest: Bristol Myers Squibb to invest $2.3B in Houston manufacturing campus

Pharmaceutical companies are making significant investments in manufacturing infrastructure, with a notable focus on expanding capacity within the United States. Eli Lilly and Resilience announced a $750 million partne

UK approval of Eli Lilly oral weight-loss pill

2 clusters · 30 sources · last updated 29 days ago

Latest: Eli Lilly's Foundayo pill receives first European approval in the UK

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorized Eli Lilly’s oral GLP-1 receptor agonist, marketed as Foundayo (orforglipron). This decision makes the United Kingdom the first European nat